Quantcast

Latest Nektar Therapeutics Stories

2014-08-21 16:24:44

Twice-Weekly Prophylactic Regimen Resulted in 95% Reduction in Median Annualized Bleed Rate Compared to On-Demand DEERFIELD, Ill., Aug. 21, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) reports Baxter International Inc. today announced positive results from its Phase 3 pivotal clinical trial of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)], which met its primary...

2014-07-31 16:29:07

SAN FRANCISCO, July 31, 2014 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2014. Cash and investments in marketable securities at June 30, 2014 were $301.4 million as compared to $309.1 million at March 31, 2014. "The second half of 2014 will be an exciting time for Nektar as we look forward to significant milestones for a number of our late-stage clinical programs," said Howard W. Robin, President and Chief...

2014-07-22 20:22:40

SAN FRANCISCO, July 22, 2014 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2014 on Thursday, July 31, 2014, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT). The press release and a live audio-only Webcast of the conference call can be...

2014-07-07 08:27:44

Editor Note: For more information about this release, please scroll to bottom. LONDON, July 7, 2014 /PRNewswire/ -- The US markets on Thursday, July 3, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 17,068.26, up 0.54% and the NASDAQ Composite closed at 4,485.93, up 0.63%. The S&P 500 finished the session 0.55% higher at 1,985.44. During the trading session, nine out of ten sectors finished on a higher note. The S&P 500 Health Care Sector...

2014-06-19 16:26:04

SAN FRANCISCO, June 19, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) reported that partner AstraZeneca today announced that the New England Journal of Medicine (NEJM) has published results of two pivotal Phase III studies - KODIAC-4 and KODIAC-5 of naloxegol, an investigational treatment for opioid-induced constipation (OIC). Opioids play an important role in chronic pain relief by binding to mu-receptors in the brain, but they also bind to mu-receptors in the bowel. That is why...

2014-06-12 16:26:24

SAN FRANCISCO, June 12, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) reported today that partner AstraZeneca announced that the majority of US Food and Drug Administration (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) members voted that the FDA should not require cardiovascular outcomes trials for the peripherally-acting mu-opioid receptor antagonist (PAMORA) class of drugs, which includes MOVANTIK(TM )(naloxegol oxalate), an investigational...

2014-06-12 12:28:55

LONDON, June 12, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Moderate Pain - Pipeline Review, H1 2014 http://www.reportbuyer.com/pharma_healthcare/treatments/moderate_pain_pipeline_review_h1_2013.html Moderate Pain - Pipeline Review, H1 2014 Summary Global Markets Direct's, 'Moderate Pain - Pipeline Review, H1 2014', provides an overview of the Moderate Pain's therapeutic pipeline. This report provides comprehensive information on the therapeutic...

2014-06-11 08:28:42

SAN FRANCISCO, June 11, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR), a biopharmaceutical company developing novel pain and cancer therapeutics, today announced that NASDAQ has halted trading of the company's common stock. The U.S. Food and Drug Administration's (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) is meeting on June 11-12, 2014 to discuss potential cardiovascular risk associated with peripherally-acting opioid receptor antagonists which...

2014-06-01 08:20:34

NKTR-214 combined with anti-PD-1 or anti-CTLA-4 provides significant tumor growth inhibition in both EMT6 breast and CT26 colon tumor models SAN FRANCISCO, June 1, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced positive preclinical data for NKTR-214, a new investigational cancer immunotherapy which selectively activates the IL-2 receptor complex and is being developed as a potential treatment for multiple cancers. The results were presented today at the 2014 ASCO...

2014-05-31 16:20:13

Single agent NKTR-102 exceeds primary endpoint with fifty-five percent of patients achieving six-week progression-free survival and fifteen percent of patients achieving partial response SAN FRANCISCO, May 31, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) announced today new data from an investigator-sponsored Phase 2 study of NKTR-102 (etirinotecan pegol) in patients with Avastin-refractory high-grade glioma conducted at Stanford Cancer Institute under the direction of...


Word of the Day
blee
  • Color; hue; complexion.
This word is Middle English in origin.
Related